0
0.5
1
1.5
2+
Mortality
77%
unadjusted
Improvement
Relative Risk
ICU admission
48%
unadjusted
Hospitalization
52%
unadjusted
Casirivimab/i.. Cooper et al. EARLY TREATMENT
Is early treatment with casirivimab/imdevimab beneficial for COVID-19?
Retrospective 9,682 patients in the USA
Lower hospitalization with casirivimab/imdevimab (p<0.000001)
c19early.org
Cooper et al., Open Forum Infectious D.., Oct 2021
Favors casirivimab/im..
Favors control